---
date: "2024-01-09 16:50:59" # 2021-07-14
title: "Illumina Shines Bright with Strong Q4 and Fiscal Year 2023 Results"
# image: "images/plots/{{titleSlag}}.png"
author: "justin-guese"
draft: false
---
tickers: <a href='https://finance.yahoo.com/quote/JNJ' target='_blank'>JNJ</a>, <a href='https://finance.yahoo.com/quote/ILMN' target='_blank'>ILMN</a> 

source: <a href='https://www.benzinga.com/news/earnings/24/01/36559887/illumina-shares-trading-higher-after-confirming-partnership-with-johnson-johnson-unit' target='_blank'>Benzinga</a>

#### tickers affected by this

| ticker | polarity | why? |
|------------|------------|------------|
| JNJ | positively | The ticker JNJ could be positively affected by this partnership as it indicates Janssen Research & Development's interest in utilizing Illumina's molecular residual disease assay, which could potentially lead to advancements in cancer research and treatment. |
| ILMN | positively | The positive Q4 results and the partnership with Janssen Research & Development indicate strong growth potential and increased market demand for Illumina's products and services, which could lead to higher revenue and profitability for the company, positively impacting the ticker ILMN. |



#### our strategies and bots using these tickers

None so far...

## summary

# Illumina, Inc. Shares Trade Higher After Strong Q4 Results

Illumina, Inc. (ILMN) shares are trading higher after the company announced its preliminary financial results for the fourth quarter (Q4) and fiscal year 2023. The company reported preliminary consolidated revenue of approximately $1.115 billion for Q4, which represents a 3% increase compared to Q4 2022. The analyst consensus for revenue stands at $1.07 billion.

In addition, Illumina reported core Illumina revenue of approximately $1,090 million for Q4, a 2% increase year over year. The company also reported a preliminary consolidated non-GAAP operating margin of approximately 3.8% for Q4.

During Q4 2023, Illumina shipped 79 NovaSeq X instruments, bringing the total number of instruments shipped for fiscal year 2023 to 352. The full fourth quarter and fiscal year 2023 results will be announced after the market closes on Thursday, Feb. 8.

Furthermore, Illumina recently signed an agreement with Janssen Research & Development, a unit of Johnson & Johnson (JNJ). This collaboration will focus on the development of Illumina's novel molecular residual disease (MRD) assay, which is a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA).

Following the announcement of these strong results and the partnership with Janssen Research & Development, Illumina, Inc. shares are trading higher by 7.26% to $143.38 on the last check Tuesday.

Please note that this article is for informational purposes only and does not constitute investment advice.